News >

Varlitinib Misses Primary Endpoint in Frontline Gastric Cancer Trial

Gina Columbus @ginacolumbusonc
Published: Monday, Jan 14, 2019

Mark McHale, MD

Mark McHale, MD

Frontline varlitinib (ASLAN001) added to mFOLFOX6 was not found to significantly reduce tumor size after 12 weeks of therapy compared with mFOLFOX6 alone in patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer, missing the primary endpoint of a phase II study, according to ASLAN Pharmaceuticals, the company developing the pan-HER inhibitor.

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer. Aslan Pharmaceuticals. Published January 14, 2019." . Accessed January 14, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication